{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.4","upperLimit":"42.3","value":"32.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"}],"units":"Participants"}],"description":"Confirmed ORR was defined as the percentage of participants who had a confirmed CR or PR as determined by investigator per RECIST v1.1. A CR was defined as disappearance of all TLs and PR was defined as \\>=30% decrease in the sum of the dms of TL, taking as reference the baseline sum of dms as long as criteria for PD were not met.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants harboring tumors with specific HER2 activating mutations received T-DXd 5.4 mg/kg via IV infusion on Day 1 of each cycle (21 days), every 3 weeks until RECIST v1.1-defined PD, withdrawal of consent, or until any other of the discontinuation criteria was met.","id":"OG000","title":"T-DXd"}],"paramType":"NUMBER","populationDescription":"The FAS consisted of all participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Tumor scans performed at screening, then q6w +/- 1 week relative to the date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)","title":"Confirmed ORR as Per RECIST v1.1 Using Investigator Assessment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}